Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Two Poziotinib Presentations at ESMO Virtual Congress 2020! They did it! They finally are doing something that met or are above expectations as opposed to having timeline expectations pass by. At the last Quarterly CC, they mentioned they were shooting to get the pozi cohort 2 data presentation at ESMO but weren't sure on that. When I heard that then I said "Ok, there is a good possibility they can do this but based on their past history, it ain't going to happen" but it is going to happen. And the other good thing about this is, if they got their act together for these presentations there is a good chance they got their act together for the pre NDA meeting w the FDA and we'll hear about it sooner rather than later. Kudos to Spectrum and looking forward to more detail about pozi.

Spectrum Pharmaceuticals Announces Two Presentations for Poziotinib at ESMO Virtual Congress 2020
September 14 2020 - 07:00AM
Business Wire

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a presentation of the results for Cohort 2 from its Phase 2 clinical trial, ZENITH20, evaluating poziotinib in previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations. In addition, a poster presentation of results from a single site expanded access program will also be presented for poziotinib in the treatment of patients with advanced NSCLC with EGFR or HER2 exon 20 insertion mutations. These presentations will take place as part of the European Society for Medical Oncology (ESMO) Virtual Congress 2020 Science Weekend to be held September 19 – 21, 2020. Details of the presentations are as follows:

Title: ZENITH20, a multinational, multi-cohort Phase 2 study of poziotinib in NSCLC patients with EGFR or HER2 Exon 20 insertion mutations
Speaker: Mark A. Socinski, M.D.
Session: On-Demand Mini Oral Session
Date and Time: September 18, 2020, 09:00 hours CEST, pre-release of mini oral sessions
Presentation Number: LBA60

Abstract Title: Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 mutations; initial results from a single site expanded assess program
Speaker: Arsela Prelaj, M.D.
Session: On-Demand E-Poster Display
Date and Time: September 17, 2020, 09:00 hours CEST, pre-release of e-posters on demand
Presentation Number: 1388P

Access to the presentations is available to members of ESMO and can be found here: esmo.org/meetings/esmo-virtual-congress-2020/registration.

https://ih.advfn.com/stock-market/NASDAQ/spectrum-pharmaceuticals-SPPI/stock-news/83249566/spectrum-pharmaceuticals-announces-two-presentatio